BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 29452772)

  • 21. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
    Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
    Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
    Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
    Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
    Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
    Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
    Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma.
    Saito K; Arai E; Maekawa K; Ishikawa M; Fujimoto H; Taguchi R; Matsumoto K; Kanai Y; Saito Y
    Sci Rep; 2016 Jun; 6():28932. PubMed ID: 27357243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
    Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
    J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
    Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
    Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
    Xiao Y; Meierhofer D
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
    Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
    Eichelberg C; Minner S; Isbarn H; Burandt E; Terracciano L; Moch H; Kell A; Heuer R; Chun FK; Sauter G; Fisch M; Tennstedt P
    World J Urol; 2013 Aug; 31(4):847-53. PubMed ID: 22009118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries.
    Marquardt A; Solimando AG; Kerscher A; Bittrich M; Kalogirou C; Kübler H; Rosenwald A; Bargou R; Kollmannsberger P; Schilling B; Meierjohann S; Krebs M
    Front Oncol; 2021; 11():621278. PubMed ID: 33791209
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.
    Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J
    Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma.
    Slater AA; Alokail M; Gentle D; Yao M; Kovacs G; Maher ER; Latif F
    Epigenetics; 2013 Mar; 8(3):252-67. PubMed ID: 23428843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.